Literature DB >> 8558146

A study of oligoclonal band negative multiple sclerosis.

A Z Zeman1, D Kidd, B N McLean, M A Kelly, D A Francis, D H Miller, B E Kendall, P Rudge, E J Thompson, W I McDonald.   

Abstract

OBJECTIVES: To determine whether oligoclonal band (OCB) negative multiple sclerosis is a reliable diagnosis and, if so, whether it has a distinctive prognosis.
METHODS: Retrospective and matched prospective comparison of the clinical and laboratory features of patients with clinical definite multiple sclerosis with and without intrathecal synthesis of oligoclonal IgG.
RESULTS: Thirty four patients were identified with apparent OCB negative clinically definite multiple sclerosis. The results of oligoclonal banding proved to have been equivocal in 14 of 34; the clinical diagnosis of multiple sclerosis was questionable in 8 of 34. The remaining 12 patients with "true" OCB negative multiple sclerosis were significantly less disabled than matched OCB positive controls. Re-examination of CSF-serum pairs from six OCB negative patients showed that three remained OCB negative while three showed evidence of intrathecal synthesis of OCBs.
CONCLUSIONS: OCB negative clinically definite multiple sclerosis is rare and should be diagnosed with caution; in unequivocal cases it seems to have a relatively benign prognosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558146      PMCID: PMC486185          DOI: 10.1136/jnnp.60.1.27

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis.

Authors:  M K Sharief; E J Thompson
Journal:  Ann Neurol       Date:  1991-02       Impact factor: 10.422

2.  Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials, and intra-blood-brain barrier IgG synthesis.

Authors:  R W Baumhefner; W W Tourtellotte; K Syndulko; V Waluch; G W Ellison; L W Meyers; S N Cohen; M Osborne; P Shapshak
Journal:  Arch Neurol       Date:  1990-01

3.  Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update.

Authors:  G Keir; R W Luxton; E J Thompson
Journal:  Ann Clin Biochem       Date:  1990-09       Impact factor: 2.057

4.  Cerebrospinal fluid immunoglobulins and multiple sclerosis. Correspondence with magnetic resonance imaging and visually evoked potential changes.

Authors:  F A Müller; P E Hänny; W Wichmann; W Fierz; M R Dürsteler
Journal:  Arch Neurol       Date:  1989-04

5.  The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord.

Authors:  D H Miller; I E Ormerod; P Rudge; B E Kendall; I F Moseley; W I McDonald
Journal:  Ann Neurol       Date:  1989-11       Impact factor: 10.422

6.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

7.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.

Authors:  A J Thompson; A G Kermode; D G MacManus; B E Kendall; D P Kingsley; I F Moseley; W I McDonald
Journal:  BMJ       Date:  1990-03-10

8.  A long-term prospective study of optic neuritis: evaluation of risk factors.

Authors:  M Sandberg-Wollheim; H Bynke; S Cronqvist; S Holtås; P Platz; L P Ryder
Journal:  Ann Neurol       Date:  1990-04       Impact factor: 10.422

9.  Multiple sclerosis. The problem of incorrect diagnosis.

Authors:  R A Rudick; R B Schiffer; K M Schwetz; R M Herndon
Journal:  Arch Neurol       Date:  1986-06

10.  Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation.

Authors:  M A Farrell; J C Kaufmann; J J Gilbert; J H Noseworthy; H A Armstrong; G C Ebers
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

View more
  21 in total

Review 1.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Thomas Brücke; Peter Bayer; Wolfgang Hübl; Walter Hübl
Journal:  J Neurol       Date:  2008-07-17       Impact factor: 4.849

Review 3.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

Review 4.  [Cerebrospinal fluid diagnostics in multiple sclerosis].

Authors:  K Ruprecht; H Tumani
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

5.  Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients.

Authors:  Maria Anagnostouli; Foteini Christidi; Ioannis Zalonis; Chryssoula Nikolaou; Dimitrios Lyrakos; Nikolaos Triantafyllou; Ioannis Evdokimidis; Constantinos Kilidireas
Journal:  Neurol Sci       Date:  2015-07-01       Impact factor: 3.307

6.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors:  Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

Review 7.  The potential role of B cell-targeted therapies in multiple sclerosis.

Authors:  Aaron Boster; Daniel P Ankeny; Michael K Racke
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

8.  B cells limit epitope spreading and reduce severity of EAE induced with PLP peptide in BALB/c mice.

Authors:  Jeri-Anne Lyons; Michael J Ramsbottom; Robert J Mikesell; Anne H Cross
Journal:  J Autoimmun       Date:  2008-06-09       Impact factor: 7.094

9.  Rituximab combination therapy in relapsing multiple sclerosis.

Authors:  Anne H Cross; Robyn S Klein; Laura Piccio
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

10.  MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfillment of Barkhof's criteria but different lesion patterns.

Authors:  Hagen B Huttner; Peter D Schellinger; Tobias Struffert; Gregor Richter; Tobias Engelhorn; Teresa Bassemir; Mathias Mäurer; Meritxell Garcia; Stefan Schwab; Martin Köhrmann; Arnd Doerfler
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.